Interferon clinical use: modern view on efficacy and safety. Literature review


Cite item

Full Text

Abstract

Interferons (IFN) were find about 65 years ago and during this time it was studied structure, types, cells producing this cytokines and genes coding of IFN. It was paid a great attention to IFN functions and biologic role in anti-viral and anti-tumor immunity, and in systemic inflammatory and autoimmune reactions. By biologic effects, which arise in organism by IFN, administrations for IFN clinical use were formed: viral infections and malignancies therapy. Currently, proposed clinical IFN use are scale down, because of not only new (including targeted) drugs, but also increased reports about long-term side effects, caused by IFN. One of the most serious side effects are autoimmune disorders, which make us reconsider IFN therapy to more safety drugs.

Full Text

Restricted Access

About the authors

Timur T. Valiev

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
Moscow, Russia

References

  1. Khanna N R, Gerriets V. Interferon. In: StatPearls [Internet]. StatPearls Publishing 2020. https://www.ncbi.nlm.nih.gov/books/NBK555932/
  2. Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019; 50 (4): 907-23.
  3. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 2014; 32: 513-45.
  4. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67.
  5. Booy S, Hofland L, van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 2015; 35: 327-39.
  6. Ronnblom L. The type I interferon system in etiopathogenesis of autoimmune diseases. Upsala J Med Sci 2011; 116: 227-37.
  7. Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014; 2014: 970315.
  8. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39 (Suppl. 1): S93-8.
  9. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11: 571-611.
  10. Razaghi A, Owens L, Heimann K. Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. J Biotechnol 2016; 240: 48-60.
  11. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
  12. Alspach E, Lussier DM, Schreiber RD. Interferon у and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol 2019; 11: a028480.
  13. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
  14. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
  15. Sleijfer S, Bannink M, Van Gool AR et al. Side effects of interferon-alpha therapy. Pharm World Sci 2005; 27 (6): 423-31.
  16. Torkildsen 0, Myhr KM, B0 L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 2016; 23 (1): 18-27.
  17. Miller CH, Maher SG, Young HA Clinical Use of Interferon-gamma. Ann N Y Acad Sci 2009; 1182: 69-79.
  18. Lasfar A, Zloza A, Cohen-Solal KA. IFN-lambda therapy: current status and future perspectives. Drug Discov Today 2016; 21 (1): 167-71.
  19. Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomized trial. Lancet 2001; 358: 866-9.
  20. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
  21. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
  22. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
  23. Yao JC, Guthrie KA, Moran C et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus beva-cizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35: 1695-703.
  24. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 2008; 372: 117-26.
  25. Hansson J, Aamdal S, Bastholt L et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomized phase 3 trial. Lancet Oncol 2011; 12: 144-52.
  26. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
  27. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
  28. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376: 221-34.
  29. Kappos L, Wiendl H, Selmaj K et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2015; 373: 1418-28.
  30. Khan UT, Tanasescu R, Constantinescu CS. PEGylated IFNb-1a in the treatment of multiple sclerosis. Expert Opin Biol Ther 2015; 15: 1077-84.
  31. Newsome SD, Kieseier BC, Arnold DL et al. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. J Neurol 2016; 263: 1778-87.
  32. Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J Neurol 2003; 250 (4): IV3-IV8.
  33. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013; 13 (7): 535-42.
  34. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proceed Nat Acad Sci 2008; 105 (19): 7034-9.
  35. Huang Y, Li M-H, Hou M. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobil Pancreat Dis Intern 2017; 16 (5): 470-9.
  36. Dash S, Aydin Y, Widmer KE et al. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020; 7: 45-76.
  37. Morgan RL, Baack B, Smith BD et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma a meta-analysis of observational studies. Ann Intern Med 2013; 158 (5): 329.
  38. Rutledge SM, Zheng H, Li DK et al. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatol Res 2019; 5: 31.
  39. Waziry R, Hajarizadeh B, Grebely J et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 67 (6): 1204-12.
  40. Greenberg HB, Pollard RB, Lutwick LI et al. Effect of Human Leukocyte Interferon on Hepatitis B Virus Infection in Patients with Chronic Active Hepatitis. New Eng J Med 1976; 295 (10): 517-22.
  41. Yang J, Zhao LS. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report. Virol J 2009; 6: 97.
  42. Sun J, Ding H, Chen G et al. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. BMC Gastroenterol 2019; 19 (1): 65.
  43. Terrault NA, Bzowej NH, Chang K-M et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2015; 63 (1): 261-83.
  44. Tarhini AA, Lee SJ, Li X et al. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res 2019; 25 (2): 524-32.
  45. Di Trolio R, Simeone E, Di Lorenzo G et al. The use of interferon in melanoma patients: A systematic review. Cytokine Growth Factor Rev 2015; 26 (2): 203-12.
  46. Mocellin S, Pasquali S, Rossi CR et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
  47. Jacobs L, O’Malley J, Freeman A et al. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214 (4524): 1026-8.
  48. Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol 2019; 10: 2040620719870052.
  49. Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-72.
  50. Mascarenhas JO, Kosiorek HE, Prchal JT et al. Results of the myeloproliferative neoplasms -research consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Blood 2018; 132: 577.
  51. Gisslinger H, Klade C, Georgiev P et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Blood 2018; 132: 579.
  52. Меликян АЛ., Суборцева И.Н., Гилязитдинова Е.А. и др. Цепэгинтерферон альфа^ в лечении хронических миелопролиферативных заболеваний. Терапевтический архив. 2018; 90 (7): 23-9. [Melikyan A.L., Subortseva I.N., Gilyazitdinova E.A. et al. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Therapeutic Archive. 2018; 90 (7): 23-9 (in Russian).]
  53. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4): 655-61.
  54. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2009; 74 (1): 17-24.
  55. Goodin DS, Ebers GC, Cutter G et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNb-1b study. BMJ Open 2012; 2 (6): e001972.
  56. Jakimovski D, Kolb C, Ramanathan M et al. Interferon в for multiple sclerosis. Cold Spring Harb Perspect Med 2018; 8: a032003.
  57. Armstrong-James D, Teo IA, Shrivastava S et al. Exogenous Interferon-y Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients. Am J Transplant 2010; 10 (8): 1796-803.
  58. Gamaletsou MN, Sipsas NV, Kontoyiannis DP et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-y. Diagnos Microbiol Infect Dis 2012; 74 (4): 409-11.
  59. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55.
  60. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res 2011; 17: 6118-24.
  61. Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112 (5): 982-94.
  62. Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxici-ties associated with high-dose Interferon Alfa-2b therapy. J Clin Oncol 2002; 20 (3): 3703-18.
  63. Verma DS, Spitzer G, Zander AR et al. Human leucocyte interferon preparation-mediated block of granulopoietic differentiation in vitro. Exp Hematol 1981; 9 (1): 63-76.
  64. Ortega JA, Ma A, Shore NA et al. Suppressive effect of interferon on erythroid cell proliferation. Exp Hematol 1979; 7 (3): 145-9.
  65. Essers MAG, Offner S, Blanco-Bose WE et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature 2009; 458 (7240): 904-8.
  66. Sato T, Onai N, Yoshihara H et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 2009; 15 (6): 696-700.
  67. Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B72. J Immunol 1996; 157 (2): 522-8.
  68. Nishiwaki H, Ogura Y, Miyamoto K et al. Interferon alfa induces leucocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996; 114 (6): 726-30.
  69. Gutman H, Schachter J, Stopel E et al. Impaired platelet aggregation in melanoma patients treated with interferon- alpha-2b adjuvant therapy. Cancer 2002; 94 (3): 780-5.
  70. Islam M, Frye RF, Richards TJ et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8 (8): 2480-7.
  71. VanGool AR, Kruit WH, Engels FK et al. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003; 25 (1): 11-20.
  72. Pinto EF, Andrade C. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem. Curr Neuropharmacol 2016; 14 (7): 743-8.
  73. Kolb-MKurer A, Goebeler M, MKurer M. Cutaneous Adverse Events Associated with Interferon-p Treatment of Multiple Sclerosis. Int J Mol Sci 2015; 16: 14951-60.
  74. Ozlu E, Karadag AS, Akdeniz N et al. Morphea secondary to interferon beta1b injection: a case and review of the literature. Dermatol Online J 2019; 25 (4): 10.
  75. Gao D, He M, Xu Q et al. Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma. Mult Scler Relat Dis 2019; 32: 33-6.
  76. Burman P, Karlsson FA, Eberg K et al. Autoimmune thyroid disease in interferon-treated patients. Lancet 1985; 2: 100-1.
  77. Karlsson-Parra A, Burman P, Hagberg H et al. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-a). Clin Exp Immunol 1990; 81: 72-5.
  78. Ronnblom LE, Alm GV, Eberg KE. Possible induction of systemic lupus erythematosus by interferon-a treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227 (3): 207-10.
  79. Ronnblom LE, Alm GV, Eberg KE. Autoimmunity after a-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-83.
  80. Hooks JJ, Moutsopoulos HM, Geis SA et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301 (1): 5-8.
  81. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 401-6.
  82. Bengtsson A, Sturfelt G, Truedsson L et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000; 9: 664-71.
  83. Hjelmervik TO, Petersen K, Jonassen I et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534-44.
  84. Baechler EC, Batliwalla FM, Reed AM et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006; 210: 120-37.
  85. Higgs BW, Liu Z, White B et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheumatic Dis 2011; 70 (11): 2029-36.
  86. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
  87. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-5.
  88. Strandberg L, Ambrosi A, Espinosa A et al. Interferon-a induces upregulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008; 28 (3): 220-31.
  89. Vallin H, Perers A, Alm GV et al. Anti-doublestranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-a inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-13.
  90. Bave U, Magnusson M, Eloranta M-L et al. FcgRIIa is expressed on natural IFN-a producing cells (plasmacytoid dendritic cells) and is required for the IFN-a production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-302.
  91. Lovgren T, Eloranta ML, Bave U et al. Induction of interferon-a production in plas-macytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861-72.
  92. Munoz LE, van Bavel C, Franz S et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008; 17: 371-5.
  93. Lande R, Ganguly D, Facchinetti V et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3: 73ra19.
  94. Garcia-Romo GS, Caielli S, Vega B et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3: 73ra20.
  95. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575-85.
  96. Lovgren T, Eloranta ML, Kastner B et al. Induction of interferon-a by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren’s syndrome autoantigenassociated RNA. Arthritis Rheum 2006; 54: 1917-27.
  97. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
  98. McClain MT, Heinlen LD, Dennis GJ et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11: 85-9.
  99. Bave U, Nordmark G, Lovgren T et al. Activation of the type I interferon system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185-95.
  100. Eloranta ML, Barbasso SH, Ulfgren AK et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro52/Ro60 autoantibodies. Arthritis Rheum 2007; 56: 3112-24.
  101. Eloranta ML, Franck-Larsson K, Lovgren T et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69: 1396-402.
  102. Shiozawa S, Kuroki Y, Kim M et al. Interferon-a in lupus psychosis. Arthritis Rheum 1992; 35: 417-22.
  103. Santer DM, Yoshio T, Minota S et al. Potent induction of IFN-a and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009; 182: 1192-201.
  104. Fairhurst AM, Mathian A, Connolly JE et al. Systemic IFN-a drives kidney nephritis in B6. Sle123 mice. Eur J Immunol 2008; 38: 1948-60.
  105. Kaplan MJ, Salmon JE. How does IFN-alpha insult the vasculature? Let me count the ways. Arthritis Rheum 2011; 63: 334-6.
  106. Denny MF, Thacker S, Mehta H et al. Interferon-a promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110: 2907-15.
  107. Lood C, Amisten S, Gullstrand B et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116: 1951-7.
  108. Li J, Fu Q, Cui H et al. Interferon-a priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-a and atherosclerosis in lupus. Arthritis Rheum 2011; 63: 492-502.
  109. Niessner A, Shin MS, Pryshchep O et al. Synergistic proinflammatory effects of the antiviral cytokine interferon-a and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116: 2043-52.
  110. Taniguchi K, Petersson M, Hyoglund P et al. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A 1987; 84: 3405-9.
  111. Brocker EB, Zwadlo G, Holzmann B et al. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988; 41: 562-7.
  112. Lollini PL, Bosco MC, Cavallo F et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer 1993; 55: 320-9.
  113. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
  114. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-48.
  115. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008; 8: 74-80.
  116. Brody JR, Costantino CL, Berger AC et al. Expression of indoleamine 2,3-dioxyge-nase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009; 8: 1930-4.
  117. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-21.
  118. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3 889-900.
  119. Irmler IM, Gajda M, Br€auer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 2007; 179: 6228-36.
  120. Manoury-Schwartz B, Chiocchia G, Bessis N et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997; 158: 5501-6.
  121. Herlyn M, Guerry D, Koprowski H. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol 1985; 134: 4226-30.
  122. Tsujisaki M, Igarashi M, Sakaguchi K et al. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol 1987; 138: 1310-6.
  123. Hemon P, Jean-Louis F, Ramgolam K et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011; 186: 5173-83.
  124. Maio M, Altomonte M, Tatake R et al. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 1991; 88: 282-9.
  125. Pena J, Alonso C, Solana R. et al. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 1990; 20: 2445-8.
  126. Beatty GL, Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 2000; 165: 5502-8.
  127. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
  128. Wischhusen J, Waschbisch A, Wiendl H. Immune-refractory cancers and their little helpers-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol 2007; 17: 459-68.
  129. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000; 61: 1102-7.
  130. Cho HI, Lee YR, Celis E. Interferon y limits the effectiveness of melanoma peptide vaccines. Blood 2011; 117: 135-44.
  131. Zaidi MR, Davis S, Noonan FP et al. Interferon-y links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469: 548-53.
  132. DeNardo DG, Barreto JB, Andreu P et al. CD4( ) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
  133. Porter GA, Abdalla J, Lu M et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001; 8: 116-22.
  134. Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011; 32: 57-65.
  135. Passegue, E. Wagers AJ, Giuriato S et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 2005; 202: 1599-611.
  136. Selleri C, Sato T, Anderson S et al. Interferon-gamma and tumor necrosis factoralpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538-46.
  137. Broxmeyer HE, Williams DE, Lu L et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interfe-ron-gamma. J Immunol 1986; 136: 4487-95.
  138. Hwang JH, Kim SW, Lee HJ et al. Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1. Int J Hematol 2006; 84: 143-50.
  139. Zeng W, Miyazato A, Chen G et al. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006; 107: 167-75.
  140. Caux C, Moreau I, Saeland S et al. Interferon-gamma enhances factor-dependent myeloid proliferation of human CD34+ hematopoietic progenitor cells. Blood 1992; 79: 2628-35.
  141. Brugger W, MOcklin W, Heimfeld S et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 1993; 81: 2579-84.
  142. Kawano Y, Takaue Y, Hirao A et al. Synergistic effect of recombinant interferongamma and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood 1991; 77: 2118-21.
  143. Zhao X, Ren G, Liang L et al. Brief Report: Interferon y Induces Expansion of Lin-Sca1 + C Kit+ Cells. Stem cells. 2010; 28 (1): 122-6.
  144. Belyaev NN, Brown DE, Diaz AIG et al. Induction of an IL7-R+ c-Kit hi myelolym-phoid progenitor critically dependent on IFN-y signaling during acute malaria. Nat Immunol 2010; 11 (6): 477-85.
  145. Baldridge MT, King KY, Boles NC et al. Quiescent haematopoietic stem cells are activated by IFN-g in response to chronic infection. Nature 2010; 465: 793-7.
  146. Fermo E, Bianchi P, Barcellini W et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogen 2004; 31: 267-9.
  147. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162-8.
  148. Kitagawa M, Saito I, Kuwata T et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-54.
  149. WHO Pharmacological Management of Pandemic Influenza A (H1N1) 2009 Part II: Review of Evidence: Revised February 2010. Geneva. World Health Organisation, 2010; p. 21-61. There are no published clinical randomized controlled trials or observational studies of current intranasal interferon preparations for the treatment of influenza.
  150. Роговая O.C., Измайлова Л.Ш., Сербина О.О. К вопросу об изучении патогенеза антипролиферативного действия противовирусных препаратов. Инфекционные болезни. 2020; 18 (2): 48-56.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies